<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834193</url>
  </required_header>
  <id_info>
    <org_study_id>18/22.09.2020</org_study_id>
    <nct_id>NCT04834193</nct_id>
  </id_info>
  <brief_title>Wet-suction Versus Slow-pull for EUS-FNB of Solid Lesions</brief_title>
  <acronym>WEST-FNB</acronym>
  <official_title>Wet-suction Versus Slow-pull Technique for Endoscopic Ultrasound-guided Fine-needle Biopsy of Solid Lesions: a Multicentric Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Ospedaliera Universitaria Integrata Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Azienda Ospedaliera Universitaria Integrata Verona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized cross-over study investigating the impact of two different suction techniques on&#xD;
      histological yield and sample quality of specimens collected by endoscopic ultrasound biopsy&#xD;
      from solid lesions using histology needles.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Histologic yield</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of samples containing a tissue &quot;core&quot; (yes/no) for histological evaluation, defined as an intact piece of tissue of at least 550 μ</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tissue integrity</measure>
    <time_frame>6 months</time_frame>
    <description>Tissue integrity will be evaluated by attributing a score from zero to 3 (3 represents the better outcome), according to the following score system:&#xD;
0: No cells/tissue&#xD;
Cytological specimen (disaggregated cells representative of the target lesion not allowing for tissue architectural assessment)&#xD;
Histologic microfragments (sample adequate for histological evaluation, namely an architecturally intact piece of tissue but without a &quot;core&quot;)&#xD;
Histologic &quot;core&quot; (defined as an architecturally intact piece of tissue measuring at least 550 μ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood contamination</measure>
    <time_frame>6 months</time_frame>
    <description>Blood contamination will be evaluated by attributing a score from zero to 3 (3 represents the better outcome), according to the following score system:&#xD;
0: Only blood&#xD;
High blood contamination (&gt;50% of the surface)&#xD;
Moderate blood contamination (25-50% of the surface)&#xD;
Low blood contamination (&lt;25% of the surface)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor fraction</measure>
    <time_frame>6 months</time_frame>
    <description>The rate of samples containing an adequate tumor fraction ≥20 percent (i.e., ≥ 20 percent tumor cells in a background of benign nucleated cells).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>6 months</time_frame>
    <description>Diagnostic accuracy (defined as the ratio between the sum of true positive and true negative values divided by the number of lesions) will be calculated for each study arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Endoscopic Ultrasound</condition>
  <condition>Fine-needle Aspiration</condition>
  <arm_group>
    <arm_group_label>WET-SUCTION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The stylet will be removed and the needle will be pre-flushed with 1-2mL of saline. The lesion will then be punctured, and suction will be applied using a 10-mL pre-vacuum syringe. The sample collected will be pushed into a formalin vial with saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLOW-PULL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After puncturing the lesion, the stylet will be slowly and gradually withdrawn for at least 40cm. The sample will be pushed into formalin using the stylet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopic ultrasound-guided fine-needle biopsy</intervention_name>
    <description>Solid lesions will be sampled under endoscopic ultrasound guidance using the two techniques (wet-suction and slow-pull)</description>
    <arm_group_label>SLOW-PULL</arm_group_label>
    <arm_group_label>WET-SUCTION</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Solid pancreatic lesions 3 1cm&#xD;
&#xD;
          -  Peri-GI tract lymph nodes 3 1cm&#xD;
&#xD;
          -  Peri-GI tract masses&#xD;
&#xD;
          -  Lesions of the GI wall&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pancreatic cystic lesions (more than 50% of the volume)&#xD;
&#xD;
          -  Diameter of lesion ≤ 1 cm&#xD;
&#xD;
          -  Lesion not seen at EUS&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Coagulopathy (platelet count &lt;50.000/mm3 and/or international normalized ratio &gt;1.5);&#xD;
&#xD;
          -  Severe cardiorespiratory dysfunction precluding endoscopy;&#xD;
&#xD;
          -  Failure to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefano Francesco Crinò, MD</last_name>
    <phone>0039 0458126169</phone>
    <email>stefanofrancesco.crino@aovr.veneto.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Azienda Ospedaliera Integrata Verona</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Francesco Crinò, MD</last_name>
      <phone>00390458126169</phone>
      <email>stefanofrancesco.crino@aovr.veneto.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Ospedaliera Universitaria Integrata Verona</investigator_affiliation>
    <investigator_full_name>Stefano Francesco Crinò, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 18, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT04834193/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

